D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm adjusted the company’s model for the new shares. The analyst says Lineage enters 2025 with “strong” operational progress, bolstered by a recent capital raise that extends its cash runway to support ongoing clinical trials and development programs. Key catalysts in the year ahead include pivotal updates from the OpRegen program for dry age-related macular degeneration, further advancement of the VAC platform in oncology, and progress in collaboration initiatives, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Cell Therapeutics price target raised to $9 from $7 at H.C. Wainwright
- Lineage Therap Announces $66 Million Direct Offering
- Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
- Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital
- Lineage Cell Therapeutics Reports Q3 2024 Highlights
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue